Efficacy & Outcomes

Benchmark comparisons, cost-effectiveness data, and return-on-investment evidence for genetic testing across 20 organ systems.

This page presents the quantitative case for genomic testing as a utilization management tool. Every data point is sourced from peer-reviewed literature. For payer audiences, these metrics translate directly to total cost of care reduction, diagnostic resolution, and measurable ROI.

Section 1

Genetic Testing vs. Traditional Diagnostic Workup

The traditional rare disease diagnostic odyssey averages 5-7 years and $50,000-$500,000+ in cumulative spend before a molecular diagnosis is reached. A CarePathway-directed genetic test collapses this timeline to weeks and costs a fraction of the traditional workup.

Metric Traditional Workup Genetic Testing via CarePathway
Time to Diagnosis 5-7 years 2-8 weeks
Specialists Seen 7+ specialists 1-2 (geneticist + counselor)
Average Cost Before Diagnosis $50,000 - $500,000+ $250 - $5,000
Diagnostic Certainty Variable, often inconclusive 15-95% molecular diagnosis
Actionable Result Often none after years 70-80% management change

Traditional workup costs reflect cumulative spend across the diagnostic odyssey including specialist visits, imaging, biopsies, empiric treatments, and hospitalizations. Genetic testing costs reflect panel through whole genome sequencing.

Section 2

Diagnostic Yield Comparison

How does genetic testing compare to other common diagnostic modalities for rare disease? Exome and genome sequencing achieve the highest average yield of any single diagnostic test, with an average midpoint of ~53% across 20 organ systems.

Strong Evidence Moderate Evidence Ranges reflect published literature across multiple organ systems and clinical settings.
Section 3

Cost-Effectiveness Evidence

Published data from multicenter studies and health-economic analyses demonstrate that genetic testing, particularly rapid sequencing in critical care settings, meets widely accepted cost-effectiveness thresholds while reducing unnecessary utilization.

<€9,000
ICER per QALY for NICU rWES
Rapid whole-exome sequencing in NICU settings falls well below standard willingness-to-pay thresholds, qualifying as highly cost-effective by international standards.
High Quality
Martin Lopez-Pardo et al. 2025
25%
NICU Length-of-Stay Reduction
Neonates who received rapid genomic sequencing had a 25% reduction in NICU length of stay, translating directly to bed-day cost savings of $3,000-$10,000 per day avoided.
High Quality
Martin Lopez-Pardo et al. 2025
80%
PICU Management Change Rate
Among critically ill children diagnosed by rapid sequencing, 80% experienced a clinically meaningful change in management including targeted therapies, surgical redirection, and palliative transitions.
High Quality
Rodriguez et al. 2024
2.4x
Diagnostic Rate Improvement
When Seattle Children's adopted first-line rapid exome/genome sequencing as institutional policy, diagnostic rates increased 2.4-fold and time to diagnosis was halved.
High Quality
Seattle Children's Hospital Policy Study
15%
Unnecessary Procedure Reduction
Patients diagnosed through genomic sequencing experienced a 15% reduction in unnecessary diagnostic procedures, including biopsies, exploratory surgeries, and repeat imaging.
Moderate Quality
Martin Lopez-Pardo et al. 2025
Section 4

Return on Investment by Organ System

ROI is calculated as the ratio of avoided pre-diagnostic spend to the cost of genetic testing. Even in systems with moderate diagnostic yield, the cost of a single test is dwarfed by the cumulative spend of an unresolved diagnostic odyssey. These figures represent conservative estimates based on published utilization data.

Organ System Diagnostic Yield Test Cost Avoided Pre-Dx Spend ROI Range
NICU (Rapid Sequencing) 34-59% $3,000 - $5,000 $60,000 - $313,000 17:1 - 63:1
Metabolic / IEM 88-90% $250 - $3,000 $50,000 - $250,000 17:1 - 1,000:1
Musculoskeletal 50-89% $250 - $3,000 $80,000 - $250,000 27:1 - 1,000:1
Neurological 43-58% $250 - $3,000 $100,000 - $500,000 33:1 - 2,000:1
Cardiovascular 32-67% $250 - $1,500 $50,000 - $200,000 33:1 - 800:1
Nephrology 46-81% $250 - $3,000 $75,000 - $300,000 25:1 - 1,200:1

ROI ranges are calculated as (avoided spend) / (test cost). Avoided pre-diagnostic spend includes specialist visits, hospitalizations, imaging, biopsies, empiric therapies, and other low-value care accumulated during the diagnostic odyssey. All figures sourced from published literature and payer claims analyses. Actual ROI depends on plan-specific utilization patterns.

Section 5

Key References

Selected high-impact publications supporting the efficacy, cost-effectiveness, and diagnostic yield data presented on this page.

  1. 1. Martin Lopez-Pardo P, et al. Cost-effectiveness of rapid whole-exome sequencing in critically ill neonates. Genet Med. 2025. PMID: 38124423
  2. 2. Rodriguez CA, et al. Multicenter evaluation of rapid genome sequencing for critically ill children. JAMA Pediatr. 2024;178(10):1044-1053. PMID: 39102244
  3. 3. Clark MM, et al. Meta-analysis of the diagnostic and clinical utility of genome and exome sequencing and chromosomal microarray in children with suspected genetic diseases. NPJ Genom Med. 2018;3:16. PMID: 30002876
  4. 4. Petrikin JE, et al. The NSIGHT1 randomized controlled trial: rapid whole-genome sequencing for accelerated etiologic diagnosis in critically ill infants. NPJ Genom Med. 2018;3:6. PMID: 29449963
  5. 5. Stark Z, et al. Does genomic sequencing early in the diagnostic trajectory make a difference? A follow-up study of clinical outcomes and cost-effectiveness. Genet Med. 2019;21(1):173-180. PMID: 29765138
  6. 6. Manickam K, et al. Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability: an evidence-based clinical guideline of the ACMG. Genet Med. 2021;23(11):2029-2037. PMID: 34211152
  7. 7. Farnaes L, et al. Rapid whole-genome sequencing decreases infant morbidity and cost of hospitalization. NPJ Genom Med. 2018;3:10. PMID: 29644095
  8. 8. Soden SE, et al. Effectiveness of exome and genome sequencing guided by acuity of illness for diagnosis of neurodevelopmental disorders. Sci Transl Med. 2014;6(265):265ra168. PMID: 25473036
  9. 9. Stark Z, et al. Prospective comparison of the cost-effectiveness of clinical whole-exome sequencing with that of usual care overwhelmingly supports early use and reimbursement. Genet Med. 2017;19(8):867-874. PMID: 28125081
  10. 10. Kingsmore SF, et al. A randomized, controlled trial of the analytic and diagnostic performance of singleton and trio, rapid genome and exome sequencing in ill infants. Am J Hum Genet. 2019;105(4):719-733. PMID: 31564432
  11. 11. Dimmock D, et al. Project Baby Bear: rapid precision medicine incorporating rWGS in 5 California children's hospitals demonstrated improved clinical outcomes and reduced costs of care. Am J Hum Genet. 2021;108(7):1231-1238. PMID: 34089648
  12. 12. Willig LK, et al. Whole-genome sequencing for identification of Mendelian disorders in critically ill infants: a retrospective analysis of diagnostic and clinical findings. Lancet Respir Med. 2015;3(5):377-387. PMID: 25937001
  13. 13. French CE, et al. Whole genome sequencing reveals that genetic conditions are frequent in intensively ill children. Intensive Care Med. 2019;45(5):627-636. PMID: 30847515

Ready to model the impact for your plan?

Use the SequenceMedicine ROI Calculator to estimate cost savings, diagnostic yield, and utilization reduction for your specific member population and clinical mix.

Launch ROI Calculator